Sai Parenterals Q1 FY27: Net profit jumps 975% YoY

Key takeaway from the June quarter

Sai Parenterals Limited reported a sharp year-on-year improvement in profitability for the quarter ended June 30, 2026 (Q1 FY27). The company posted a steep rise in revenue from operations and a significant jump in profit, reflecting a strong turnaround from the same period last year. Alongside the numbers, the board also approved changes in how previously planned capital expenditure will be deployed. Instead of putting certain funds into facility upgrades and an R&D centre, the company plans to use that allocation to buy majority stakes in two entities. These proposals are subject to shareholder approval.

Standalone performance: profit rises on higher operating revenue

On a standalone basis, Sai Parenterals reported net profit of ₹88.75 million in Q1 FY27. This marked a 975% year-on-year increase compared with ₹8.25 million in Q1 FY26. Revenue from operations rose 175% year-on-year to ₹527.79 million, up from ₹192.00 million in the year-ago quarter. Total income for the quarter stood at ₹561.92 million versus ₹204.42 million a year earlier. Total expenses rose to ₹443.62 million compared with ₹192.50 million in Q1 FY26.

Profit before tax came in at ₹118.30 million, compared with ₹11.92 million in Q1 FY26. Basic EPS was ₹2.01, up from ₹0.31 in the same quarter last year. Compared with the immediately preceding quarter (Q4 FY26), the company reported revenue from operations of ₹527.79 million versus ₹567.94 million, and net profit after tax of ₹88.75 million versus ₹99.49 million. The data suggests that the larger swing was driven by the year-on-year base effect, with the sequential comparison showing softer numbers.

Consolidated performance: revenue grows sharply, profit improves

On a consolidated basis, net profit after tax was ₹79.23 million in Q1 FY27. This compares with ₹14.15 million in Q1 FY26, indicating a strong year-on-year increase. Consolidated revenue from operations reached ₹1,786.72 million, up from ₹333.91 million in the corresponding quarter last year. Total comprehensive income for the consolidated group was reported at ₹79.23 million.

The consolidated revenue figure indicates a much larger scale of operations than the standalone business. However, the gap between standalone and consolidated profitability underscores the importance of subsidiary-level performance, costs, and integration-related impacts. The company’s disclosures also point to varying profitability across the group entities during the quarter.

Subsidiary watch: Noumed revenue, but quarterly loss

Noumed Pharmaceuticals Pty Limited, a step-down subsidiary, reported total revenue of ₹1,037.09 million during the period cited in the update. Despite this revenue, Noumed incurred a loss of ₹89.53 million. The update noted that this may be impacting the consolidated bottom line despite overall profit growth at the group level.

This detail matters because consolidated performance reflects both the scale benefits of the group and the drag from loss-making units. Investors typically track whether such losses narrow over time as integration stabilises and operating leverage improves. The company has not provided additional granular drivers for the loss in the text provided, so the numbers are best read as an indicator of mixed profitability within the group.

Board decision: capex reallocated to two majority acquisitions

Beyond the quarter’s earnings, the board approved strategic shifts in capital allocation. Sai Parenterals will utilise ₹838.34 million that was originally earmarked for upgrading Unit I and Unit II manufacturing facilities to acquire a 60% equity stake in Saicriti Pharma Private Limited. The acquisition involves a critical care sterile injectable manufacturing facility at Gummadidala, Hyderabad, with a total estimated development cost of ₹2,149.60 million.

Separately, ₹180.23 million that had been allocated to establish a new Research and Development Centre will be redirected to acquire a 60% stake in Prathyak Laboratories Private Limited. Prathyak is described as an established pharmaceutical R&D platform with a portfolio of 124 products under development. Both acquisitions are subject to shareholder approval, and the stated intent is to achieve strategic objectives with lower execution risk and shorter timelines.

Corporate actions: trading window closure and earnings call date

The company also announced the closure of its trading window for dealing in Sai Parenterals’ securities. The window was shut from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026.

Separately, the Q1 earnings conference call for FY 2026-27 is scheduled for August 12, 2026. Such calls are typically where management discusses quarterly performance, business conditions, capital allocation decisions, and near-term priorities.

FY26 snapshot: scale-up year and IPO funding

For FY26, consolidated revenue reached ₹3,809.90 million (₹380.99 crore), a 140.37% year-on-year increase. EBITDA was ₹472.10 million (₹47.21 crore), up 33.29% year-on-year, while profit after tax was ₹143.70 million (₹14.37 crore), up 45.52% year-on-year.

The company also stated it completed its IPO in March 2026, raising ₹2,850 million (₹285 crore). It had indicated plans to utilise ₹1,300 million (₹130 crore) towards capacity expansion, manufacturing upgrades and the establishment of a dedicated R&D centre in India. These earlier capex intentions are notable in light of the new board-approved proposal to redirect part of the earmarked funds toward acquisitions.

Guidance and planned investments mentioned in updates

The company has provided guidance for FY27, targeting revenue of ₹7,500 million (₹750 crore) with an EBITDA margin of 17%. The text attributes this to long-term contracts and vertical integration, along with the integration of its Australian subsidiary.

Separately, the update also mentions ongoing capex of around ₹4,400 million (₹440 crore) expected to be completed in FY27. Another section refers to a total investment exceeding ₹4,200 million (₹420 crore), comprising ₹1,180 million (₹118 crore) for India, an Australian plant investment of about ₹2,915 million (₹291.5 crore) and ₹180 million (₹18 crore) for a new R&D center. These figures are presented as part of broader planning disclosures and should be read as stated targets and plans rather than confirmed outcomes.

Key numbers at a glance

Why the quarter matters for investors

The quarter stands out for two reasons supported by the disclosed numbers. First, the standalone business reported a sharp year-on-year jump in profitability alongside a strong rise in revenue, indicating a materially stronger operating quarter compared with Q1 FY26. Second, the consolidated numbers show much higher revenue scale, but the subsidiary-level disclosure highlights that not all parts of the group are contributing equally to profit.

The board’s decision to redirect funds toward acquiring majority stakes in a sterile injectable facility and an R&D platform is another key development. It signals a preference for buying operating or near-operating assets instead of building entirely in-house, with the company explicitly citing lower execution risk and shorter timeframes. The next formal checkpoint for additional context is the scheduled earnings conference call on August 12, 2026.

Conclusion

Sai Parenterals’ Q1 FY27 results showed a sharp year-on-year rebound in standalone profit and a large rise in consolidated revenue, alongside disclosure of a loss at Noumed despite strong subsidiary revenue. The board has also approved reallocating certain planned capex toward two 60% stake acquisitions, subject to shareholder approval. Investors will watch for further details around these proposals, Noumed’s performance, and any execution updates in the scheduled earnings call on August 12, 2026.